Impact of chronic obstructive pulmonary disease on survival after chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
BACKGROUND Chimeric antigen receptor T-cell (CAR T-cell) therapy is the standard of care for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The impact of pre-existing chronic obstructive pulmonary disease (COPD) on outcomes of LBCL after CAR-T cell therapy are not well characterized. This study aimed at evalua...